tradingkey.logo

Dare Bioscience Inc

DARE
2.170USD
+0.010+0.46%
收盘 12/24, 16:00美东报价延迟15分钟
30.23M总市值
亏损市盈率 TTM

Dare Bioscience Inc

2.170
+0.010+0.46%

关于 Dare Bioscience Inc 公司

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

Dare Bioscience Inc简介

公司代码DARE
公司名称Dare Bioscience Inc
上市日期Apr 10, 2014
CEOJohnson (Sabrina Martucci)
员工数量21
证券类型Ordinary Share
年结日Apr 10
公司地址3655 Nobel Dr Ste 260
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92122-1050
电话18589267655
网址https://www.darebioscience.com/
公司代码DARE
上市日期Apr 10, 2014
CEOJohnson (Sabrina Martucci)

Dare Bioscience Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--
Ms. Mardee Haring-layton
Ms. Mardee Haring-layton
Chief Accounting Officer
Chief Accounting Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Law Custodial Inc
7.76%
The Vanguard Group, Inc.
2.76%
AMH Equity, Ltd.
1.63%
Geode Capital Management, L.L.C.
0.86%
Johnson (Sabrina Martucci)
0.56%
其他
86.42%
持股股东
持股股东
占比
Law Custodial Inc
7.76%
The Vanguard Group, Inc.
2.76%
AMH Equity, Ltd.
1.63%
Geode Capital Management, L.L.C.
0.86%
Johnson (Sabrina Martucci)
0.56%
其他
86.42%
股东类型
持股股东
占比
Corporation
9.86%
Investment Advisor
3.69%
Hedge Fund
2.04%
Investment Advisor/Hedge Fund
1.20%
Individual Investor
0.97%
Research Firm
0.13%
其他
82.10%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
59
1.01M
6.94%
--
2025Q3
60
1.01M
11.35%
+107.08K
2025Q2
62
909.51K
16.50%
+77.11K
2025Q1
63
832.40K
15.91%
-575.66K
2024Q4
63
782.40K
14.61%
+121.87K
2024Q3
63
660.53K
14.09%
+53.91K
2024Q2
68
606.70K
13.87%
+32.71K
2024Q1
71
573.99K
13.86%
-587.68K
2023Q4
76
555.67K
14.26%
-521.78K
2023Q3
73
1.08M
7.88%
+535.07K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
328.33K
2.44%
--
--
Jun 30, 2025
AMH Equity, Ltd.
193.60K
1.44%
+29.30K
+17.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
95.45K
0.71%
-450.00
-0.47%
Jun 30, 2025
Johnson (Sabrina Martucci)
80.17K
0.59%
+1.00
+0.00%
Apr 17, 2025
Susquehanna International Group, LLP
106.89K
0.79%
+48.72K
+83.77%
Jun 30, 2025
Renaissance Technologies LLC
71.80K
0.53%
+1.20K
+1.70%
Jun 30, 2025
Walters-Hoffert (Lisa)
36.96K
0.27%
--
--
Apr 17, 2025
State Street Investment Management (US)
23.52K
0.17%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
15.01K
0.11%
-6.71K
-30.89%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
公告日期
类型
比率
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1

常见问题

Dare Bioscience Inc的前五大股东是谁?

Dare Bioscience Inc 的前五大股东如下:
The Vanguard Group, Inc.持有股份:328.33K,占总股份比例:2.44%。
AMH Equity, Ltd.持有股份:193.60K,占总股份比例:1.44%。
Geode Capital Management, L.L.C.持有股份:95.45K,占总股份比例:0.71%。
Johnson (Sabrina Martucci)持有股份:80.17K,占总股份比例:0.59%。
Susquehanna International Group, LLP持有股份:106.89K,占总股份比例:0.79%。

Dare Bioscience Inc的前三大股东类型是什么?

Dare Bioscience Inc 的前三大股东类型分别是:
Law Custodial Inc
The Vanguard Group, Inc.
AMH Equity, Ltd.

有多少机构持有Dare Bioscience Inc(DARE)的股份?

截至2025Q4,共有59家机构持有Dare Bioscience Inc的股份,合计持有的股份价值约为1.01M,占公司总股份的6.94%。与2025Q3相比,机构持股有所增加,增幅为-4.42%。

哪个业务部门对Dare Bioscience Inc的收入贡献最大?

在--,--业务部门对Dare Bioscience Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI